Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 87


T cell homeostatic proliferation elicits effective antitumor autoimmunity.

Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA, Theofilopoulos AN.

J Clin Invest. 2002 Jul;110(2):185-92.


Vaccine therapy of established tumors in the absence of autoimmunity.

Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.

Clin Cancer Res. 2003 May;9(5):1837-49.


CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response.

Sfondrini L, Besusso D, Bronte V, Macino B, Rossini A, Colombo MP, Ménard S, Balsari A.

Cancer Immunol Immunother. 2004 Aug;53(8):697-704. Epub 2004 Mar 18.


Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.

Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ.

J Exp Med. 1996 Jan 1;183(1):87-97.


NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells.

Zecher D, Li Q, Oberbarnscheidt MH, Demetris AJ, Shlomchik WD, Rothstein DM, Lakkis FG.

J Immunol. 2010 Jun 15;184(12):6649-57. doi: 10.4049/jimmunol.0903729. Epub 2010 May 14.


Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.

Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.

Eur J Immunol. 2009 Oct;39(10):2725-36. doi: 10.1002/eji.200939543.


Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.

Tanaka Y, Koido S, Ohana M, Liu C, Gong J.

J Immunol. 2005 Feb 1;174(3):1274-80.


Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.

Hu HM, Winter H, Urba WJ, Fox BA.

J Immunol. 2000 Oct 15;165(8):4246-53.


CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.

Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, Prieto J, Borrás-Cuesta F, Lasarte JJ.

J Immunol. 2003 Dec 1;171(11):5931-9.


Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.

Kilinc MO, Gu T, Harden JL, Virtuoso LP, Egilmez NK.

J Immunol. 2009 Apr 1;182(7):4217-25. doi: 10.4049/jimmunol.0802793.


Allogeneic MHC gene transfer enhances an effective antitumor immunity in the early period of autologous hematopoietic stem cell transplantation.

Kobayashi A, Hara H, Ohashi M, Nishimoto T, Yoshida K, Ohkohchi N, Yoshida T, Aoki K.

Clin Cancer Res. 2007 Dec 15;13(24):7469-79.


Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.

Marshall NA, Galvin KC, Corcoran AM, Boon L, Higgs R, Mills KH.

Cancer Res. 2012 Feb 1;72(3):581-91. doi: 10.1158/0008-5472.CAN-11-0307. Epub 2011 Dec 9.


Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.

Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.

Clin Immunol. 2009 Nov;133(2):184-97. doi: 10.1016/j.clim.2009.07.008. Epub 2009 Aug 7.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk